Table 3.

Treatment characteristics and severe adverse events

All patients (n = 25)Responders OR (n = 10)Nonresponders NR (n = 14)P OR vs. NR
Treatment characteristics (median, range)
 Days in hospitala19 (15–36)17.5 (15–36)20 (15–27)0.12
 Units RBC transfusion5 (1–25)5 (2–14)5 (1–25)0.52
 Units PLT transfusion7 (3–17)7 (3–14)7 (3–17)0.81
 Days with neutrophils < 0.5 × 109/L8 (4–13)8 (5–12)9 (4–13)0.79
 Dose IL2 administered, MIUb112 (50–135)107 (58–135)112 (50–135)0.75
 % IL2 administeredc95 (60–100)93 (60–100)96 (60–100)0.57
Severe adverse eventsd (n)
 Febrile neutropenia241014
 Infections, verifiede
 Urinary tract11
 Pneumoniaf22
 Aspiration pneumonia11
 Central venous catheter211
 Pulmonary edema11
 Renal failure11
 Atrial fibrillation11
 Diarrhea11
 Hemoperitonium11
 Petechia211
 Venous thromboembolism11
 Delirium22
 Mortality (grade 5)1NANANA
Autoimmune reactions, any grade (n)
 Vitiligo22
 Uveitis11
 Vasculitis11
 Pernicious anemia11
  • NOTE: The table shows treatment characteristics and severe adverse events related to treatment (≤8 weeks after treatment).

  • Abbreviations: NR, nonresponders; OR, objective responders; PLT, platelets; RBC, red blood cell.

  • aMeasured from the first day of chemotherapy to discharge.

  • bTotal dose of IL2 administered in MIU.

  • cPercent IL2 administered of prescheduled dose.

  • dAccording to the CTCAE v 3.0.

  • eInfection verified by microbiological tests.

  • fPneumonia verified/likely by chest X-ray.